Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 4Genitourinary 2Dermatologic 2Thoracic 1Other solid neoplasm 1Other hematologic neoplasm 1Lymphoid 1CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 86Lung Neoplasms 32Small Cell Lung Carcinoma 18Melanoma 17Mesothelioma 13Neoplasms 11Colorectal Neoplasms 9Carcinoma, Renal Cell 9Squamous Cell Carcinoma of Head and Neck 7Neoplasm Metastasis 7Mesothelioma, Malignant 7Carcinoma, Transitional Cell 7Ovarian Neoplasms 6Diabetes Mellitus, Insulin-Dependent, 12 6Urinary Bladder Neoplasms 5Triple Negative Breast Neoplasms 5Pancreatic Neoplasms 5Liver Neoplasms 5Endometrial Neoplasms 5Carcinoma, Hepatocellular 5Uterine Cervical Neoplasms 4Stomach Neoplasms 4Kidney Neoplasms 4Brain Neoplasms 4Carcinoma, Merkel Cell 3Skin Neoplasms 2Sarcoma 2Prostatic Neoplasms 2Lung Diseases 2Head and Neck Neoplasms 2

Interventions

Nivolumab 4pembrolizumab 2durvalumab 2regorafenib 1fludarabine phosphate 1fludarabine 1danvatirsen 1avelumab 1atezolizumab 1Ipilimumab 1Interleukin-2 1Immunoglobulin G 1Docetaxel 1Disulfides 1Cyclophosphamide 1Clinical Trials, Phase II as Topic 1ALT-803 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Turcot syndrome × Ipilimumab × Thoracic × Clear all
NCT06362369 2026-04-13

A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy

7 Hills Pharma, LLC

Phase 1/2 Recruiting
126 enrolled
DermatologicGastrointestinalGenitourinaryOther solid neoplasmThoracic

Turcot syndrome, Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Kidney Neoplasms, Liver Neoplasms, Melanoma, Neoplasm Metastasis, Skin Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡